Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

When standard cancer treatments begin to fail, especially in aggressive or advanced stages, oncologists are increasingly ...

The ARANOTE trial (NCT04736199) represents a significant step forward in the treatment landscape for patients with metastatic ...

Pharmaceutical scientists, clinicians, nurses and pharmacists from the National University of Singapore (NUS) and National University Hospital (NUH) have shown that a reduced dose of abiraterone ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on the phase 2 trial.

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...